Nearly 75 health workers underwent dummy vaccination at Bhopal in Madhya Pradesh on Saturday as part of the first dry run of COVID-19 vaccine programme in the state, an official said.
The mock vaccination programme was conducted at three health centres in the state capital- Gandhi Nagar community health centre (CHC), Govindpura CHC and L N Hospital, he said.
As part of the process, SMSs were sent to the health workers, in which they were asked to come to these health facilities, he added.
"After the dummy vaccination shots were given to them, these health workers were asked to wait for 30 minutes at the centres so that they are kept under observation, like in the actual vaccination plan," the official said.
According to him, when the actual COVID-19 vaccination programme is rolled out, a person who is administered the vaccine, will have to wait for 30 minutes for observation by the health authorities.
In case that person feels uneasy or experiences some complications, he or she would be treated, he said.
"Everything went as per the plan during the dry run. The dummy vaccines had been sent to the three health facilities in time and smoothly via cold chain," the official added.
He claimed that as per the plan, 20,000 to 25,000 coronavirus warriors would first receive the vaccine when the inoculation process begins in Madhya Pradesh.
The Union Health Ministry had earlier said that the dry run for COVID-19 vaccination is being conducted by all state and union territory administrations on Saturday to test the linkages between planning and implementation and to identify the challenges.
It had said that the objective of the dry run for COVID-19 vaccine introduction is to assess the operational feasibility in the use of Co-WIN application in field environment, to test the linkages between planning and implementation and to identify the challenges and guide way forward prior to actual implementation.
The dry run will also equip the state and UT administration in management of vaccine supply, storage and logistics including cold chain management, it had said.
On Friday, the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) recommended granting permission for restricted emergency use of Oxford-AstraZeneca vaccine Covishield, being manufactured by the Serum Institute of India, paving the way for the roll-out of the first COVID-19 shot in the country in the next few days.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU